- Home
- BIIB vs GFI Comparison
BIIB vs GFI Comparison
Compare BIIB & GFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- GFI
- Stock Information
- Founded
- BIIB 1978
- GFI 1887
- Country
- BIIB United States
- GFI South Africa
- Employees
- BIIB 7605
- GFI N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- GFI Precious Metals
- Sector
- BIIB Health Care
- GFI Basic Materials
- Exchange
- BIIB Nasdaq
- GFI Nasdaq
- Market Cap
- BIIB 20.6B
- GFI 16.9B
- IPO Year
- BIIB 1991
- GFI 2007
- Fundamental
- Price
- BIIB $140.60
- GFI $18.71
- Analyst Decision
- BIIB Buy
- GFI Hold
- Analyst Count
- BIIB 27
- GFI 3
- Target Price
- BIIB $220.50
- GFI $16.60
- AVG Volume (30 Days)
- BIIB 1.5M
- GFI 3.0M
- Earning Date
- BIIB 02-12-2025
- GFI 03-04-2025
- Dividend Yield
- BIIB N/A
- GFI 2.07%
- EPS Growth
- BIIB 40.28
- GFI N/A
- EPS
- BIIB 11.18
- GFI 1.38
- Revenue
- BIIB $9,675,900,000.00
- GFI $5,201,600,000.00
- Revenue This Year
- BIIB N/A
- GFI $16.72
- Revenue Next Year
- BIIB $1.57
- GFI $24.42
- P/E Ratio
- BIIB $12.65
- GFI $14.11
- Revenue Growth
- BIIB N/A
- GFI 1.30
- 52 Week Low
- BIIB $128.51
- GFI $12.28
- 52 Week High
- BIIB $238.00
- GFI $19.80
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- GFI 61.80
- Support Level
- BIIB $135.02
- GFI $18.59
- Resistance Level
- BIIB $141.69
- GFI $19.80
- Average True Range (ATR)
- BIIB 4.00
- GFI 0.48
- MACD
- BIIB 0.04
- GFI -0.07
- Stochastic Oscillator
- BIIB 59.44
- GFI 58.24
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About GFI Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.